Marina Biotech said this week that the Canadian patent office has issued the company a notice of allowance for a patent application covering amphoteric liposomal formulations and their use for the delivery of nucleic acids and other compounds with therapeutic application.
The application, No. 2,438,116, specifically relates to Marina's Smarticles technology, which it acquired from Novosom last summer (GSN 7/29/2010).
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
